VIVITROL is
one dose a month

Watch the Video to learn about
directions for use

Gluteal intramuscular injection of VIVITROL

Gluteal intramuscular injection of VIVITROL®

Vivitrol—a once-monthly
injectable1

  • VIVITROL is only available in one dose, 380 mg, and must be prepared and administered by a healthcare provider
  • VIVITROL is given as a 4 mL gluteal intramuscular injection alternating buttocks for each subsequent injection
  • VIVITROL is an extended-release microsphere formulation of naltrexone that delivers medication continuously over a one-month period (or 4 weeks)
  • VIVITROL must not be given intravenously, subcutaneously, or into adipose tissue
    • Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions

Injection site Reactions

  • VIVITROL must be prepared and administered by a healthcare provider.
  • VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases injection site reactions may be very severe.
  • Injection site reactions not improving may require prompt medical attention, including, in some cases, surgical intervention.
  • Inadvertent subcutaneous/adipose layer injection of VIVITROL may increase the likelihood of severe injection site reactions.
  • Select proper needle size for patient body habitus, and use only the needles provided in the carton.
  • Patients should be informed that any concerning injection site reactions should be brought to the attention of their healthcare provider.

VIVITROL DELIVERY OVER THE APPROVED DOSING INTERVAL

Continuous delivery of medication over the approved dosing interval1

VIVITROL is an extended-release microsphere formulation of naltrexone that delivers medication continuously over a one-month period (or 4 weeks).1

Arrow Right

The recommended dose of VIVITROL is 380 mg, delivered intramuscularly once a month (every 4 weeks).1

Arrow Right

After intramuscular injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2-3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.1

MEAN NALTREXONE CONCENTRATION1-3

Mean naltrexone concentration over 30 days

Data for oral naltrexone beyond Day 5 have been extrapolated from a study of normal healthy volunteers (n=14) given oral naltrexone 50 mg daily for 5 days.

Plasma concentrations do not necessarily correlate with clinical efficacy.

Dosage and Administration1:

VIVITROL must be prepared and administered by a healthcare provider.

Prior to initiating VIVITROL, an opioid-free duration of a minimum of 7–10 days is recommended for patients, to avoid precipitation of withdrawal that may be severe enough to require hospitalization.

VIVITROL is available in one dose, 380 mg, delivered intramuscularly every 4 weeks or once a month by a healthcare provider.

  • VIVITROL must not be administered intravenously or subcutaneously
  • Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions
  • Alternate buttocks for each subsequent injection
  • The needles provided in the carton are customized needles. VIVITROL must not be injected using any other needle. Proper needle from the carton should be selected based on body habitus
  • Administer with caution in patients with moderate to severe renal impairment, thrombocytopenia, or any other coagulation disorder
  • If a patient misses a dose, he/she should be instructed to receive the next dose as soon as possible
  • Patients reinitiating treatment with VIVITROL should be opioid-free at the time of dose administration
  • Patients should be alerted that they may be more sensitive to opioids, even at lower doses
  • See additional dosage and administration information in the VIVITROL Full Prescribing Information

VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, injection site reactions and sudden opioid withdrawal.
See Important Safety Information below. Discuss all benefits and risks with your patients. See Prescribing Information. Review Medication Guide with your patients.

Request A Representative

REQUEST A REPRESENTATIVE

Request a visit from a VIVITROL representative to learn more about how VIVITROL may help your opioid- and alcohol-dependent patients.

REQUEST A REPRESENTATIVE

VIVITROL® Co-pay Savings Program

LEARN ABOUT THE VIVITROL® CO-PAY SAVINGS PROGRAM

Learn how the VIVITROL® Co-pay Savings Program may assist eligible* patients with out-of-pocket expenses for their VIVITROL prescriptions.

LEARN MORE

References:

  1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc; rev September 2019.
  2. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480-490.
  3. Dean RL. The preclinical development of Medisorb® naltrexone, a once a month long-acting injection, for the treatment of alcohol dependence. Front Biosci. 2005;10:643-655.

*Terms and Conditions

Eligibility for Alkermes-Sponsored Co-pay Savings. This offer is only available to patients 18 years or older, with a prescription consistent with the Prescribing Information and the patient is not enrolled in, or covered by, any local, state, federal or other government program that pays for any portion of medication costs, including but not limited to Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care and Alternative Benefit Plans under the Affordable Care Act; Medigap; VA; DOD; TRICARE; or a residential correctional program.
Additional Terms of Use: This offer is not conditioned on any past, present, or future purchase, including refills. Alkermes reserves the right to rescind, revoke, or amend this offer, program eligibility, and requirements at any time without notice. This offer is limited to one per patient, may not be used with any other offer, is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade. Void where prohibited by law. Program Administrator or its designee will have the right upon reasonable prior written notice, during normal business hours, and subject to applicable law, to audit compliance with this program.